No colonoscopy n = 8194 | Colonoscopy n = 4712 | Total n = 12,906 | P value | |
---|---|---|---|---|
Mean age (SD) at diagnosis (years) | 69.4 (13.5) | 71.5 (12.0) | 70.2 (13.0) | < 0.001 |
Age at diagnosis (years) | < 0.001** | |||
< 60 | 1843 (22.5%) | 764 (16.2%) | 2607 (20.0%) | |
60–69 | 2025 (24.7%) | 1067 (22.7%) | 3092 (24.0%) | |
70–79 | 2191 (26.8%) | 1554 (33.0%) | 3745 (29.0%) | |
> 80 | 2129 (26.0%) | 1326 (28.2%) | 3455 (26.8%) | |
Sex | 0.043* | |||
Male | 4365 (54.7%) | 2447 (52.8%) | 6812 (54.0%) | |
Female | 3621 (45.3%) | 2188 (47.1%) | 5809 (46.0%) | |
Country of birth | < 0.001* | |||
Australia & NZ | 5486 (68.9%) | 3206 (70.2%) | 8692 (69.4%) | |
Europe | 1931 (24.3%) | 1153 (25.3%) | 3084 (24.6%) | |
North Africa/Middle East | 18 (0.2%) | 16 (0.4%) | 34 (0.3%) | |
Asia & Pacific Islands | 114 (1.5%) | 52 (1.2%) | 166 (1.4%) | |
Americas | 31 (0.4%) | 8 (0.2%) | 39 (0.3%) | |
Africa (other) | 370 (4.7%) | 130 (2.9%) | 500 (4.0%) | |
Indigenous | 0.100* | |||
No | 7596 (99.8%) | 4476 (99.6%) | 12,072 (99.7%) | |
Yes | 19 (0.3%) | 19 (0.4%) | 38 (0.3%) | |
Remoteness | < 0.001** | |||
Major city | 6022 (73.5%) | 3174 (67.4%) | 9196 (71.3%) | |
Inner regional | 893 (10.9%) | 508 (10.8%) | 1401 (10.9%) | |
Outer regional and remote | 1278 (15.6%) | 1029 (21.8%) | 2307 (17.9%) | |
SES disadvantage quintile | < 0.001** | |||
1st (most disadvantage) | 1884 (23.0%) | 1327 (28.2%) | 3211 (24.9%) | |
2nd | 1813 (22.1%) | 1058 (22.5%) | 2871 (22.3%) | |
3rd | 1545 (18.9) | 936 (19.9%) | 2481 (19.3%) | |
4th | 1615 (19.7%) | 809 (17.2%) | 2424 (18.8%) | |
5th (least disadvantage) | 1332 (16.3%) | 572 (12.2%) | 1904 (14.8%) | |
Local Health Network | < 0.001* | |||
Country Health SA | 2424 (29.6%) | 1689 (35.9%) | 4113 (31.9%) | |
Central Adelaide | 2507 (30.6%) | 1269 (26.9%) | 3776 (29.3%) | |
Northern Adelaide | 1628 (19.9%) | 872 (18.5%) | 2500 (19.4%) | |
Southern Adelaide | 1634 (19.9%) | 880 (18.7%) | 2514 (19.5%) | |
Median (IQR) of years survived on Dec 31st 2013 | 2.7 (0.9–5.5) | 3.0 (1.1–6.3) | 2.8 (1.0–5.7) | < 0.001 |
Cancer staging (max spread) | < 0.001** | |||
Local | 2001 (42.9%) | 1479 (49.8%) | 3480 (45.6%) | |
Regional | 1556 (33.4%) | 897 (30.2%) | 2453 (32.1%) | |
Distant | 1108 (23.8%) | 595 (20.0%) | 1703 (22.3%) | |
% cancer-specific survival by time from diagnosis | < 0.001*** | |||
At 1 year | 84.5% | 86.8% | 85.5% | |
At 3 year | 71.0% | 74.6% | 72.3% | |
At 5 year | 64.6% | 69.4% | 66.0% |